A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Sponsor: Immunovant Sciences GmbH
This observational or N/A phase trial investigates Graves' Disease and is currently actively recruiting participants. Immunovant Sciences GmbH leads this study, which shows 9 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Apr 23, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Jun 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Contact Information
- Immunovant Sciences GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece , Athens, Greece , Athens, Greece , Auckland, New Zealand , Aurora, United States , Beersheba, Israel , Bialystok, Poland , Box Hill, Australia , Brisbane, Australia , Bydgoszcz, Poland and 110 more locations